A Phase 3b, Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects with Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to see the effect (good or bad) of increasing the time between doses of Ustekinumab (Stelara) beyond the FDA-approved 12 weeks for treatment of moderate-to-severe plaque psoriasis, using the FDA approved Ustekinumab dose of 45 mg or 90 mg.
Ustekinumab was previously studied in subjects with psoriasis and is currently being studied in subjects with psoriatic arthritis and Crohn’s disease. In these studies, Ustekinumab has been generally well-tolerated.
You may be eligible to participate in this study if you:
- Are 18 years of age or older
- Have a diagnosis of moderate to severe plaque psoriasis
- Are willing to withhold other psoriasis medications during the course of the study
- Agree to avoid prolonged sun exposure and avoid other sources of ultraviolet light (including tanning booths) during the study
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.